Published in Diabetes Ther on October 31, 2016
Cardiovascular Safety of Antidiabetic Drugs in the Hospital Setting. Curr Diab Rep (2017) 0.75
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med (2002) 101.79
Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med (2008) 47.90
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med (2008) 38.76
10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med (2008) 35.49
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med (2007) 33.21
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ (1998) 32.73
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med (2005) 27.77
Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med (2008) 25.70
Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation (2014) 22.74
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med (2003) 20.06
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med (2006) 19.09
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med (2015) 18.66
Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med (2008) 18.27
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet (2006) 15.76
A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med (2009) 12.15
Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2015) 12.05
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med (2015) 9.70
Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med (2013) 8.74
Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes (2009) 8.70
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet (2009) 8.54
Achievement of goals in U.S. diabetes care, 1999-2010. N Engl J Med (2013) 7.17
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet (2015) 6.05
Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation (2014) 5.32
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med (2016) 5.24
Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med (2011) 4.76
Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ (2012) 4.68
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. N Engl J Med (2016) 4.52
Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care (2007) 4.30
Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia (2006) 3.94
Adherence to prescribed oral hypoglycaemic medication in a population of patients with Type 2 diabetes: a retrospective cohort study. Diabet Med (2002) 3.90
Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J (2011) 3.72
Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med (2015) 3.67
Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care (2013) 2.96
National trends in US hospital admissions for hyperglycemia and hypoglycemia among Medicare beneficiaries, 1999 to 2011. JAMA Intern Med (2014) 2.61
The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab (2012) 2.44
Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors. Diabetes Care (2015) 2.27
Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia (2010) 1.98
Pancreatic safety of incretin-based drugs--FDA and EMA assessment. N Engl J Med (2014) 1.95
Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med (2010) 1.92
Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther (2002) 1.80
A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes. Curr Med Res Opin (2011) 1.79
Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes Care (2013) 1.79
Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus. Ann Intern Med (2015) 1.71
National standards for diabetes self-management education and support. Diabetes Care (2014) 1.70
Cooperation between brain and islet in glucose homeostasis and diabetes. Nature (2013) 1.59
Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care (2014) 1.52
Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Clin Ther (2012) 1.51
Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among Texas Medicaid recipients. Clin Ther (2008) 1.45
Use of antidiabetic drugs in the U.S., 2003-2012. Diabetes Care (2014) 1.44
Aace/Ace comprehensive diabetes management algorithm 2015. Endocr Pract (2015) 1.43
Update on cardiovascular outcomes at 30 years of the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care (2014) 1.42
Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs (2015) 1.41
The association between the number of prescription medications and incident falls in a multi-ethnic population of adult type-2 diabetes patients: the diabetes and aging study. J Gen Intern Med (2009) 1.35
Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care (2015) 1.31
Impact of fixed-dose combination drugs on adherence to prescription medications. J Gen Intern Med (2008) 1.23
Adherence to a fixed-dose combination of rosiglitazone/glimepiride in subjects switching from monotherapy or dual therapy with a thiazolidinedione and/or a sulfonylurea. Ann Pharmacother (2010) 1.14
Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes. Diabetes Care (2010) 1.12
Fixed-dose combinations for treatment of type 2 diabetes mellitus. Adv Ther (2012) 1.09
Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co-administered with metformin. Diabetes Obes Metab (2003) 1.06
Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia (2016) 1.04
The incidence and costs of hypoglycemia in type 2 diabetes. Am J Manag Care (2011) 1.04
Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes. J Clin Endocrinol Metab (2012) 1.03
Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. Diabetes Res Clin Pract (2014) 1.02
Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes Care (2015) 1.00
Impact of metformin-induced gastrointestinal symptoms on quality of life and adherence in patients with type 2 diabetes. Postgrad Med (2010) 0.99
Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes Mellitus. Diabetes Ther (2013) 0.98
Polypharmacy in the Aging Patient: A Review of Glycemic Control in Older Adults With Type 2 Diabetes. JAMA (2016) 0.96
The DPP-4 inhibitor linagliptin restores β-cell function and survival in human isolated islets through GLP-1 stabilization. J Clin Endocrinol Metab (2013) 0.96
Is there a paradox in obesity? Cardiol Rev (2014) 0.91
Improved function and proliferation of adult human beta cells engrafted in diabetic immunodeficient NOD-scid IL2rγ(null) mice treated with alogliptin. Diabetes Metab Syndr Obes (2013) 0.89
Utilization of glucose, blood pressure, and lipid lowering medications among people with type II diabetes in the United States, 1999-2010. Ann Epidemiol (2014) 0.88
Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial. Diabetes Ther (2015) 0.86
Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies. Int J Cardiol (2016) 0.85
Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes. Clin Pharmacokinet (2015) 0.85
A retrospective study of persistence, adherence, and health economic outcomes of fixed-dose combination vs loose-dose combination of oral anti-diabetes drugs. J Med Econ (2015) 0.83
The dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus: cardiovascular safety. Postgrad Med (2012) 0.82
The Combination of DPP-4 Inhibitors Versus Sulfonylureas with Metformin After Failure of First-line Treatment in the Risk for Major Cardiovascular Events and Death. Can J Diabetes (2015) 0.81
Fixed-dose combination therapy in type 2 diabetes mellitus. Endocr Pract (2014) 0.78
Empagliflozin/linagliptin single-tablet combination: first-in-class treatment option. Int J Clin Pract (2015) 0.76
Triglyceride High-Density Lipoprotein Ratios Predict Glycemia-Lowering in Response to Insulin Sensitizing Drugs in Type 2 Diabetes: A Post Hoc Analysis of the BARI 2D. J Diabetes Res (2015) 0.76